Eli Lilly Announces Topline Results From TRANSCEND-T2D-1, Showing Reductions In A1C And Weight In First Phase 3 Trial For Treatment Of Type 2 Diabetes

Eli Lilly announced positive topline results from its Phase 3 trial TRANSCEND-T2D-1 for retatrutide, a treatment for type 2 diabetes. The trial showed that retatrutide reduced A1C levels by an average of 1.7% to 2.0% over 40 weeks, and participants on the 12 mg dose lost an average of 36.6 lbs (16.8%). Notably, there was no observed weight loss plateau, indicating continued weight loss throughout the trial period.